BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GRWD5769 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GRWD5769\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06923761-2625@assetmemo.bio
DTSTAMP:20261121T005443Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:GRWD5769: Phase 1/2 readout est. (NCT06923761)
DESCRIPTION:GRWD5769\, phase 1/2.\nStudy: EMITT-1 (ERAP Mediated Immunopept
 idome Targeting Trial - 1)\nEstimated primary completion: 30 April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/grwd5769#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06923761
URL:https://assetmemo.bio/drug/grwd5769#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
